airway
patenc
ensuredif
mmhg
oxygen
therapi
hfnc
start
hypoxemia
persist
despit
maxim
therapi
hypercapnea
progress
sever
acidosi
patient
transfer
immedi
icuassess
volum
statu
invas
andor
noninvas
hemodynam
monitor
administ
iv
fluid
andor
vasopressor
need
sever
assess
sever
cap
assess
accord
variou
sever
score
eg
pneumonia
sever
index
psi
american
thorac
societyinfecti
diseas
societi
america
atsidsa
criteria
icu
admiss
cappneumonia
sever
index
psi
moder
good
accuraci
predict
day
mortal
patient
cap
point
given
age
gender
comorbid
ill
physic
examin
find
abg
analysi
blood
chemistri
hematocrit
chest
xray
find
score
calcul
patient
classifi
psi
v
accord
final
score
mortal
rang
respect
superior
abil
detect
low
risk
patient
psi
ii
manag
outpati
wherea
iv
v
need
consist
core
element
new
onset
confus
urea
mgdl
rr
bpm
sbp
mmhg
dbp
mmhg
age
year
older
point
total
curb
manag
outpati
curb
gener
requir
ward
treatment
score
warrant
inpati
aggress
treatment
usual
icu
superior
abil
detect
high
risk
patient
simpler
version
score
away
urea
measur
without
lose
effect
detect
high
risk
patient
studi
suggest
age
group
year
better
predict
atsidsa
criteria
icu
admiss
cap
consist
major
invas
mechan
ventil
septic
shock
requir
vasopressor
minor
criteria
confus
rr
bpm
ratio
multilobar
infiltr
bun
mgdl
wbc
platelet
count
temperatur
hypotens
requir
fluid
resuscit
presenc
major
minor
criterion
requir
admiss
icu
abil
predict
icu
admiss
sensit
specif
principl
therapi
sever
cap
earli
initi
antibiot
therapi
even
initi
resuscit
measur
ongo
aim
improv
mortal
patient
sever
cap
admit
emerg
depart
ed
receiv
first
dose
antibiot
ed
itselfblood
sputum
cultur
sent
antibiot
sensit
test
start
antibiot
delay
initi
antibiot
therapyth
initi
choic
antibiot
depend
detail
indepth
histori
particular
emphasi
identifi
etiolog
cap
see
tabl
whether
patient
risk
infect
drug
resist
organ
see
tabl
initi
choic
antibiot
patient
risk
factor
betalactambeta
lactamas
inhibitor
amoxicillinclavulan
ampicillinsulbactum
cephalosporin
cefuroxim
cefotaxim
ceftriaxon
plu
macrolid
azithromycin
clarithromycin
doxycyclinerespiratori
fluoroquinolon
levofloxacin
moxifloxacin
ora
betalactam
amoxicillinclavulan
ampicillinsulbactum
cefuroxim
cefotaxim
ceftriaxon
plu
aztreonam
patient
penicillin
allergi
initi
choic
antibiot
patient
risk
factor
infect
drug
resist
organ
mention
belowpseudomona
extend
spectrum
beta
lactamas
esbl
produc
organ
antipseudomon
betalactam
piperacillintazobactam
cefepimeceftazidimeavibactam
cefoperazon
sulbactam
carbapenem
imipenem
meropenem
plu
antipseudomon
fluoroquinolon
ciprofloxacin
levofloxacin
doxycyclin
macrolid
orantipneumococc
antipseudomon
betalactam
piperacillintazobactam
cefepim
plu
aminoglycosid
amikacin
plu
macrolid
azithromycin
clarithromycin
antipseudomon
fluoroquinolon
ciprofloxacin
levofloxacin
doxycyclin
replac
betalactam
aztreonam
patient
penicillin
allergi
multidrug
resist
pseudomona
aeruginosa
suspect
give
colistinsuspicion
vancomycin
linezolidin
person
risk
aspir
cva
seizur
dysphagia
vomit
head
neck
cancer
metronidazol
clindamycinantibiot
start
cover
common
microorgan
caus
pneumonia
typic
atyp
organ
cover
use
parenter
adequ
dose
frequenc
keep
mind
pharmacokinet
pharmacodynam
drug
continuousextend
intraven
infus
antibiot
may
use
appropri
follow
antibiot
polici
hospit
present
antibiot
may
tailor
accord
local
sensit
pattern
organ
follow
investig
sent
simultan
resuscit
empir
antibiot
initi
see
tabl
sever
cap
associ
septic
shock
multiorgan
dysfunctionfailur
treat
accord
appropri
surviv
sepsi
guidelinesin
patient
copd
bronchial
asthma
aerosolis
bronchodil
use
requir
adequ
dose
frequenc
noninvas
ventil
niv
niv
tri
cautious
patient
hypoxemia
increas
work
breath
respiratori
distress
especi
copd
bronchial
asthma
patient
close
monitor
improv
appar
h
may
intub
mechan
ventil
patient
sever
hypoxemia
bilateralmultilobar
infiltr
respiratori
distress
receiv
immedi
invas
mechan
ventil
steroid
patient
vasopressor
resist
shock
given
low
dose
intraven
steroid
patient
copd
bronchial
asthma
oral
steroid
continu
equival
intraven
dose
steroid
routin
use
corticosteroid
adjunct
therapi
sever
cap
brisk
inflammatori
respons
suggest
rct
metaanalys
per
latest
guidelin
recommend
steroid
use
presenc
septic
shock
respond
vasopressor
therapi
per
surviv
sepsi
guidelinesavoid
steroid
patient
viral
aspergillu
pneumonia
immunosuppress
host
uncontrol
diabeticpati
sever
cap
receiv
routin
support
icu
measur
institut
appropri
antibiot
therapi
improv
clinic
cours
patient
appar
within
day
assess
clinic
halm
clinic
stabil
criteria
temperatur
heart
rate
bpm
respiratori
rate
bpm
sbp
mmhg
satur
arteri
tension
room
air
normal
mental
statu
normal
oral
intak
simplifi
at
criteria
improv
cough
dyspnea
absenc
fever
h
normalis
total
leukocyt
count
previou
day
adequ
oral
intak
associ
improv
biomark
crp
reduct
reduct
procalcitonin
also
act
guid
respons
patient
show
expect
clinic
respons
within
expect
timelin
label
nonrespond
reason
nonrespons
may
infect
relat
caus
treatment
failur
defin
persist
progress
pneumonia
result
need
mechan
ventil
develop
septic
shock
may
earli
within
h
late
h
may
due
variou
reason
mention
infect
pathogen
cover
initi
empir
therapi
infect
atyp
pathogen
tuberculosi
strongyloidosi
influenza
viru
nosocomi
secondari
infect
iv
infecti
complic
parapneumon
effus
empyema
lung
abscess
bronchial
obstruct
slow
respond
patient
improv
therapi
rate
slower
expect
old
age
presenc
comorbid
sever
infect
organ
like
gram
neg
bacilli
legionella
staphylococcu
aureu
predictor
slow
respons
eight
nine
day
treatment
may
need
clinic
improv
note
non
infecti
caus
malign
lung
cancer
metastat
interstiti
lung
diseas
cryptogen
organis
pneumonia
diffus
alveolar
damag
hypersensit
pneumonia
eosinophil
pneumonia
alveolar
hemorrhag
drug
fever
vascul
churgstrauss
wegen
foreign
bodi
pulmonari
embol
pulmonari
infarct
pulmonari
edema
lipoid
pneumonia
fibreopt
bronchoscopi
analysi
balendotrach
aspir
cultur
prefer
quantit
sensitivityserolog
hiv
influenza
viru
antinuclear
antibodi
antineutrophil
cytoplasm
antibodybnp
probnp
levelsddim
level
venou
doppler
lower
limbsultrasonographi
chestcomput
tomographi
chestdemonstr
presenc
effus
empyema
abscess
localis
durat
therapi
depend
clinic
respons
organ
involv
comorbid
present
biomark
respons
presenc
complicationspati
sever
cap
treat
minimum
day
gener
day
patient
afebril
h
clinic
stabl
discontinu
therapyth
durat
antibiot
may
prolong
upto
day
slow
respond
infect
pseudomona
gram
neg
bacilli
staphylococcu
presenc
complic
like
lung
abscess
empyema
presenc
extra
pulmonari
metastat
infect
mening
endocard
secondari
sever
cap
smoke
cessat
influenza
pneumococc
vaccin
